Language

English

Publication Date

7-21-2026

Journal

BMJ Open

DOI

10.1136/bmjopen-2025-111773

PMID

42481189

PMCID

PMC13404497

PubMedCentral® Posted Date

7-21-2026

PubMedCentral® Full Text Version

Post-print

Abstract

Objective: Respiratory syncytial virus (RSV) is an important viral pathogen in children, older adults and adults with certain high-risk conditions. In our prospective community-based cohort study of adults 50 years and older before the COVID-19 pandemic, the incidence of RSV acute respiratory infection (ARI) was 48.6 cases/1000 person-years (PY), which decreased to near zero during the COVID-19 pandemic. Our objective was to determine the incidence of RSV-ARI during the 2 years following the initial phase of the pandemic (2021-2022 and 2022-2023).

Design: This is a community-based prospective cohort study.

Setting: Adults living in southeast Minnesota from October 2021 to September 2022 (year 3) and October 2022 to September 2023 (year 4).

Participants: Adults≥50 years (n=2500).

Primary and secondary outcomes: We calculated incidence and attack rates for RSV-ARI as primary outcome and reported hospitalisations, pneumonia and death following ARI as secondary outcome.

Results: There were 2500 participants in the study with a mean age of 68.2 years (SD 9.3) at the start of year 3. Participants were predominantly female (60%), non-Hispanic white (96%) and residing in urban areas (76%). The incidence rate of RSV-ARI was 6.12/1000 PY (95% CI 3.42 to 10.09) in 2021-2022 and 16.40/1000 PY (95% CI 11.66 to 22.42) in 2022-2023. We noted higher attack rates of RSV-ARI during the winter months. There were no hospitalisations, pneumonia or deaths within 30 days of RSV-ARI.

Conclusions: Compared with the period before the COVID-19 pandemic, RSV-ARI incidence was lower in both 2021-2022 and 2022-2023 periods. In 2022-2023, the incidence increased 2.7-fold compared with the 2021-2022 period. The observed incidence rates, particularly the significant increase in the most recent season, underscore the continued public health relevance of RSV-ARI and support the rationale for ongoing RSV vaccination efforts to mitigate its overall burden in the population.

Keywords

Humans, Female, Incidence, Prospective Studies, Respiratory Syncytial Virus Infections, Minnesota, COVID-19, Middle Aged, Aged, Male, Hospitalization, SARS-CoV-2, Aged, 80 and over, Respiratory infections, GERIATRIC MEDICINE, Community-Based Participatory Research

Published Open-Access

yes

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.